Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACTHAR Clear all
Completed Phase 3 Interventional Results available

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

NCT02132195
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Wilmington, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Results available

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

NCT02057523
View directory record Official record
Conditions
Proteinuria, Transplant Glomerulopathy
Interventions
Acthar
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 5, 2026, 12:54 AM EDT
Completed No phase listed Observational Results available

Pilot Study Assessing Oxidative Stress in Children

NCT01052207
View directory record Official record
Conditions
Adrenal Insufficiency, Critical Illness
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^

NCT01227980
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Anxiety Disorder
Interventions
Pexacerfont, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 5, 2026, 12:54 AM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Results available

ACTHar in the Treatment of Lupus Nephritis

NCT02226341
View directory record Official record
Conditions
Lupus Nephritis
Interventions
CellCept, ACTHar gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 3 Interventional Results available

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889
View directory record Official record
Conditions
FSGS
Interventions
Acthar
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 5, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of Sulfasalazine on CRH Levels in Pregnant Women

NCT05703425
View directory record Official record
Conditions
Preterm Birth
Interventions
Sulfasalazine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

NCT06336356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Phoenix, Arizona • Tempe, Arizona • Montclair, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 12:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

NCT00001180
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
Interventions
Ovine Corticotropin-Releasing Hormone (oCRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1982 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional Results available

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

NCT02749227
View directory record Official record
Conditions
Pituitary Tumor, ACTH-producing Pituitary Tumour
Interventions
Pasireotide LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 5, 2026, 12:54 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Imaging CRF X NOP Interactions in CUD

NCT05008146
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Baseline [C-11]NOP-1A PET Scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET Scan
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 5, 2026, 12:54 AM EDT
Not listed Not applicable Interventional

Comprehensive Analysis of Relapse in Multiple Sclerosis

NCT01906684
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Tanner Foundation for Multiple Sclerosis
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 5, 2026, 12:54 AM EDT
Completed No phase listed Observational

Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism

NCT00744588
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 5, 2026, 12:54 AM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

NCT01155141
View directory record Official record
Conditions
Kidney Diseases
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 1 Interventional

Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery

NCT01839812
View directory record Official record
Conditions
Adrenal Cortex Diseases, Infant Morbidity
Interventions
Cosyntropin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 365 Days
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 5, 2026, 12:54 AM EDT
Terminated Not applicable Interventional

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

NCT01367964
View directory record Official record
Conditions
West Syndrome
Interventions
adrenocorticotropin hormone
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Months to 12 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 5, 2026, 12:54 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 5, 2026, 12:54 AM EDT
Recruiting Not applicable Interventional

Reducing Pregnancy Risks: The Mastery Lifestyle Intervention

NCT05012072
View directory record Official record
Conditions
Mental Health Wellness 1, Preterm Birth
Interventions
The Mastery Lifestyle Intervention
Behavioral
Lead sponsor
Microgen LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 5, 2026, 12:54 AM EDT
Completed Phase 2 Interventional

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

NCT01813591
View directory record Official record
Conditions
Chronic Migraine
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 5, 2026, 12:54 AM EDT